Citigroup
TCRX icon

Citigroup’s TScan Therapeutics TCRX Stock Holding History

Citigroup’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$1 – 6236
2026
Q1 		$1 Buy
+1
New +$1 ﹤0.01% 5872
2025
Q4 		– Sell
-1,088
Closed -$1.98K – 6468
2025
Q3 		$1.98K Sell
1,088
-10,684
-91% -$18.9K ﹤0.01% 5486
2025
Q2 		$17.1K Sell
11,772
-16,374
-58% -$23.7K ﹤0.01% 5113
2025
Q1 		$38.8K Sell
28,146
-12,097
-30% -$26.2K ﹤0.01% 4946
2024
Q4 		$122K Buy
40,243
+12,450
+45% +$56.4K ﹤0.01% 4733
2024
Q3 		$138K Buy
27,793
+19,347
+229% +$117K ﹤0.01% 4603
2024
Q2 		$49.4K Sell
8,446
-108,475
-93% -$854K ﹤0.01% 4584
2024
Q1 		$928K Buy
116,921
+43,758
+60% +$275K ﹤0.01% 3090
2023
Q4 		$427K Buy
+73,163
New +$335K ﹤0.01% 3520

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citigroup's TCRX Position: Q2 2026 in Review

Citigroup sold out of TScan Therapeutics (TCRX) in Q2 2026, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in TCRX in Q4 2023 and held it in 9 quarters. The position peaked at $928K in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Citigroup reported no remaining TScan Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 TScan Therapeutics share in Q2 2026, an estimated $1.
  • Citigroup first reported a position in TScan Therapeutics in Q4 2023 and held it in 9 quarters.
  • Citigroup's TScan Therapeutics position peaked at $928K in Q1 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.